Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

RET and p53 expression in thyroid follicular adenoma: A study of 52 cases with 14 years follow-up

Nor Hayati Othman, and Effat Omar, and Mohd Hamdi Mahmood, and Manoharan, Madhavan, (2005) RET and p53 expression in thyroid follicular adenoma: A study of 52 cases with 14 years follow-up. Malaysian Journal of Pathology, 27 (2). pp. 91-98. ISSN 0126-8635

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
983Kb

Official URL: http://www.mjpath.org.my/past_issue/MJP2005.2/03RET.pdf

Affiliations

Universiti Sains Malaysia. School of Medical Sciences. Dept. of Pathology
Universiti Sains Malaysia. School of Medical Sciences. Dept. of Pathology
Universiti Sains Malaysia. School of Medical Sciences. Dept. of Pathology
Universiti Sains Malaysia. School of Medical Sciences. Dept. of Pathology

Abstract

Most previous studies on RET and p53 proteins have focused on thyroid papillary carcinoma. We investigated the role of RET and p53 protein expressions using immunohistochemistry on 52 cases of thyroid follicular adenomas and studied the follow-up records of these patients. The range of follow-up period was 3 to 14 years. The patients were between 15 and 71 years of age with a median age of 34.5 years. There were 46 females and 6 males.� ��Except for 3 cases, all patients were Malays. 000The minimum volume of the tumour was 1000mm3 and the maximum was 512,000mm3 with a median of 270,000mm3. Eleven (21.2%) cases showed RET expression. RET expression was not statistically significant when cross-tabulated against sex (p=0.322), ethnicity (p=0.518), age (p=0.466) and symptom duration (p=0.144). Six����(11.5%) of 52 cases showed p53 immunopositivity. p53 expressions were also not significantly correlated to the clinical parameters above. There was no correlation between RET and p53 protein expressions. The only statistically significant finding was the association of tumour volume with duration of symptoms (p=0.05). All patients are alive at the time of writing. 3 had recurrent goitre, 2 of these were diagnosed as colloid goitre while the third was a follicular lesion. One patient suffered from depression requiring anti-depressant treatment. In conclusion, unlike papillary carcinoma in which the roles of ret and p53 oncogenes are known, their roles in influencing the behaviour of follicular adenoma has not been ascertained.

Item Type:Journal
Keywords:Follicular adenoma, RET expressions, ret gene, RET/PTC, ret/PTC, p53 expressions,clinical follow-up
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:1807

1. Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene. 1992;7:1331-7.

2. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest. 1992;89:1517-22.

3. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med. 1994;123:331-7.

4. Takahashi M. Oncogenic activation of the ret protooncogene in thyroid cancer. Crit Rev Oncog. 1995;6:35-46.

5. Pacini F, Elisei R, Romei C, Pinchera A. RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. J Endocrinol Invest. 2000;23:328-38.

6. Lam KY, Lo CY, Leung PS. High prevalence ofRET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas. Eur J Endocrinol. 2002;147:741-5.

7. Nakazawa T,Kondo T,Kobayashi Y,et al. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer. 2005;104:943-51.97

8. Ishizaka Y, Kobayashi S, Ushijima T, Hirohashi S, Sugimura T, Nagao M. Detection ofretTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene. 1991;6:1667-72.

9. Lam AK, Montone KT, Nolan KA, Livolsi VA. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum Pathol. 1998;29:565-8.

10. O’Keeffe DA, Hill AD, Sheahan K, et al. Ret-proto-oncogene analysis in medullary thyroid carcinoma. Ir J Med Sci. 1998;167:226-30.

11. Kameyama K,Takami H. Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. Endocr J. 2004;51:453-6.

12. Ministry ofHealth M. Annual Report ofMinistry ofHealth Malaysia. 1998,1999.

13. Mafauzy M, Mohamad WB, Anum MY, Musalmah M. Urinary iodine excretion in the northeast of peninsular Malaysia. Southeast Asian J Trop Med Public Health. 1995;26:138-42.

14. Madhavan M, Othman NH. Spectrum ofthyroid diseases in hospital Universiti Sains Malaysia : a study of300 consecutive cases. Mal J Med Sci. 1996;3:58.

15. Murray D. Functional Endocrine Pathology. Ottawa: Blackwell Science; 1998.

16. Dunn JT,Medeiros LJ. Endemic goitre and cretinism: Continuing threats to world health. World Health Organization. Washington D.C; 1992.

17. Omar E,Othman NH. Immunohistochemical localization of RET rearrangements in a Malaysian papillary thyroid carcinoma population. Med J Malaysia. 2003;58:461-2.

18. Omar E, Madhavan M, Othman NH. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Pathology. 2004;36:152-9.

19. Burgess JR, Dwyer T, McArdle K, Tucker P, Shugg D. The changing incidence and spectrum ofthyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab. 2000;85:1513-7.

20. Larijani B, Shirzad M, Mohagheghi MA, et al. Epidemiologic analysis of the Tehran Cancer Institute Data System Registry (TCIDSR). Asian Pac J Cancer Prev. 2004;5:36-9.

21. Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence ofpapillary thyroid carcinoma (1982-1997). Thyroid. 2002;12:141-9.

22. Satta MA, Nanni S, Della Casa S, Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000;25:151-61.

23. Hosal SA, Apel RL, Freeman JL, et al. Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior. Endocr Pathol. 1997;8:21-8.

24. Freeman J, Carroll C, Asa S, Ezzat S. Genetic events in the evolution of thyroid cancer. J Otolaryngol. 2002;31:202-6.

25. Mayr B, Potter E, Goretzki P, et al. Expression of wild-type ret,ret/PTC and ret/PTC variants in papillary thyroid carcinoma in Germany. Langenbecks Arch Surg. 1999;384:54-9.

26. Wynford-Thomas D. Molecular basis of epithelial tumorigenesis: the thyroid model. Crit Rev Oncog. 1993;4:1-23.

27. Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Horm Res. 1997;47:145-57.

28. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations ofBRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436-40.

29. Portella G, Vitagliano D, Borselli C, et al. Human N-ras,TRK-T1,and RET/PTC3 oncogenes,driven by a thyroglobulin promoter,differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res. 1999;11:421-7.

30. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004;15:319-27.

31. Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man. Mutat Res. 1995;333:123-9.

32. Beimfohr C, Klugbauer S, Demidchik EP, Lengfelder E,Rabes HM. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer. 1999;80:842-7.

33. Elisei R,Romei C,Vorontsova T,et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated,malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab. 2001;86:3211-6.

34. Cerilli LA, Mills SE, Rumpel CA, Dudley TH, Moskaluk CA. Interpretation ofRET immunostaining in follicular lesions of the thyroid. Am J Clin Pathol. 2002;118:186-93.

35. Cinti R,Yin L,Ilc K,et al. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet. 2000;88:56-61.

36. Chung DH,Kang GH,Kim WH,Ro JY. Clonal analysis of a solitary follicular nodule of the thyroid with the polymerase chain reaction method. Mod Pathol. 1999;12:265-71.

37. Feldt-Rasmussen U. Iodine and cancer. Thyroid. 2001;11:483-6.

38. Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid. 2005;15:152-7.

39. Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990;86:120-5.

40. Park KY,Koh JM,Kim YI,et al. Prevalences of Gs alpha,ras,p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf). 1998;49:317-23.

41. LiVolsi VA, Fadda G, Baloch ZW. Prognostic factors in well-differentiated thyroid cancer. Rays. 2000000000;25:163-75.

42. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo. 2004;18:189-95.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.